Roche: encouraging results in NMOSD disorders
(CercleFinance.com) - On Thursday Roche announced initial results from two Phase III studies showing that its treatment for neuromyelitis optica spectrum disease (NMOSD) was effective and well tolerated.
In patients for whom the NMO-IgG/anti-aquaporin 4 (AQP4) autoantibody could be identified, between 71% and 73% of individuals treated with Enspryng did not experience a disease relapse over a period of almost four years, the company said in a statement.
The data also show that between 90% and 91% of patients treated with Enspryng did not experience any severe relapse of the disease.
NMOSD is a group of chronic inflammatory autoimmune diseases of the central nervous system that attack the patient's immune system, including nerve cells in the spinal cord and optic nerves.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
In patients for whom the NMO-IgG/anti-aquaporin 4 (AQP4) autoantibody could be identified, between 71% and 73% of individuals treated with Enspryng did not experience a disease relapse over a period of almost four years, the company said in a statement.
The data also show that between 90% and 91% of patients treated with Enspryng did not experience any severe relapse of the disease.
NMOSD is a group of chronic inflammatory autoimmune diseases of the central nervous system that attack the patient's immune system, including nerve cells in the spinal cord and optic nerves.
Copyright (c) 2021 CercleFinance.com. All rights reserved.